Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial
Hepatology · 2023
DOI: 10.1097/hep.0000000000000046 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Hepatology, 2023. Verfasst von Hyehyun Jeong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background and Aims: The effectiveness of gemcitabine-based adjuvant chemotherapy is unclear in cholangiocarcinoma. We investigated the role of adjuvant gemcitabine plus cisplatin (GemCis) in a homogeneous group of high-risk patients with resected, lymph node–positive extrahepatic cholangiocarcinoma. Approach and Results: Adenocarcinoma of perihilar or distal bile duct with regional lymph node metastasis who underwent curative-intent surgery (R0/R1) was eligible. Patients were randomized to receive GemCis (gemcitabine 1000 mg/m 2 , cisplatin 25 mg/m 2 on days 1 and 8) or capecitabine (1250 mg/m 2 twice daily on days 1–14) every 3 weeks for 8 cycles. Primary endpoint was disease-free survival. Secondary endpoints were overall survival and safety. All p values are 1 sided and were considered significant if
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
- Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Hyehyun Jeong, Kyu-Pyo Kim, Jae Ho Jeong, Jae Hoon Lee, Ki-Hun Kim, Deok-Bog Moon, Myung Ah Lee, Se Jun Park, Hong Jae Chon, Jin-Hong Park, Changhoon Yoo
Zitieren
APA
Jeong, H., Kim, K. P., Jeong, J. H., Hwang, D. W., Lee, J. H., Kim, K. H., Moon, D. B., Lee, M. A., Park, S. J., Chon, H. J., Park, J. H., Lee, J. S., Ryoo, B. Y., & Yoo, C. (2023). Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology. https://doi.org/10.1097/hep.0000000000000046
Vancouver
Jeong H, Kim KP, Jeong JH, Hwang DW, Lee JH, Kim KH, et al. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology. 2023. doi:10.1097/hep.0000000000000046
BibTeX
@article{Jeong2023,
author = {Jeong, Hyehyun and Kim, Kyu-Pyo and Jeong, Jae Ho and Hwang, Dae Wook and Lee, Jae Hoon and Kim, Ki-Hun and Moon, Deok-Bog and Lee, Myung Ah and Park, Se Jun and Chon, Hong Jae and Park, Jin-Hong and Lee, Ji Sung and Ryoo, Baek-Yeol and Yoo, Changhoon},
title = {Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial},
journal = {Hepatology},
year = {2023},
doi = {10.1097/hep.0000000000000046}
}
EUVIMED